DNA test could Fine-Tune blood thinners for heart patients

NCT ID NCT06143709

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry studies how genetic information can help doctors choose the best antiplatelet medication for people who have had a heart stent procedure. Over 1,600 participants will provide DNA samples and be followed for 12 months to track heart events and bleeding. The goal is to learn how to personalize therapy based on genetics and other patient factors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

DNA sample collection

What this could lead to

If successful, this could help doctors personalize antiplatelet medications based on a patient's genetics, potentially reducing heart attacks and strokes while minimizing bleeding risks.

What could go wrong

This is an observational registry, not a treatment trial, so it won't directly test a new drug or therapy. Results may not lead to immediate changes in clinical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Florida

    Gainesville, Florida, 32609, United States